Can we use biomarkers in combination with self-reports to strengthen the analysis of nutritional epidemiologic studies? by Freedman, Laurence S et al.
ANALYTIC PERSPECTIVE Open Access
Can we use biomarkers in combination with
self-reports to strengthen the analysis of
nutritional epidemiologic studies?
Laurence S Freedman
1*, Victor Kipnis
2, Arthur Schatzkin
3, Nataša Tasevska
4, Nancy Potischman
5
Abstract
Identifying diet-disease relationships in nutritional cohort studies is plagued by the measurement error in self-
reported intakes.
The authors propose using biomarkers known to be correlated with dietary intake, so as to strengthen analyses of
diet-disease hypotheses. The authors consider combining self-reported intakes and biomarker levels using principal
components, Howe’s method, or a joint statistical test of effects in a bivariate model. They compared the statistical
power of these methods with that of conventional univariate analyses of self-reported intake or of biomarker level.
They used computer simulation of different disease risk models, with input parameters based on data from the lit-
erature on the relationship between lutein intake and age-related macular degeneration.
The results showed that if the dietary effect on disease was fully mediated through the biomarker level, then the
univariate analysis of the biomarker was the most powerful approach. However, combination methods, particularly
principal components and Howe’s method, were not greatly inferior in this situation, and were as good as, or bet-
ter than, univariate biomarker analysis if mediation was only partial or non-existent. In some circumstances sample
size requirements were reduced to 20-50% of those required for conventional analyses of self-reported intake.
The authors conclude that (i) including biomarker data in addition to the usual dietary data in a cohort could
greatly strengthen the investigation of diet-disease relationships, and (ii) when the extent of mediation through the
biomarker is unknown, use of principal components or Howe’s method appears a good strategy.
Introduction
One of the most challenging problems in nutritional
epidemiology is that of measurement error in dietary
reporting [1]. It is now recognized that in univariate
models these errors attenuate estimated relative risks
(RRs) and seriously reduce statistical power to detect
diet-disease relationships. In multivariate models, mea-
surement errors can cause under-estimation or over-
estimation of RRs in an unpredictable manner [2].
Efforts to tackle the problem of dietary measurement
error have included the use of biological markers of
nutritional intake. One of their main uses has been the
validation of self-report instruments. In this regard, two
classes of biomarker have been identified: recovery and
concentration biomarkers [3]. Recovery biomarkers are
those based on recovery of certain products directly
related to intake and not subject to substantial inter-
individual differences in metabolism. Only a few exam-
ples exist, including the doubly-labeled water technique
[4] for measuring energy expenditure (and hence indir-
ectly energy intake), and 24-hour urinary nitrogen [5]
for measuring protein intake. These biomarkers provide
nearly unbiased measurements of intake, and are there-
fore extremely useful for validating self-report
instruments.
Concentration biomarkers, such as serum carotenoids,
are those that are related to dietary intake but not in as
direct a manner as recovery biomarkers because their
levels are the result of complex metabolic processes. In
addition to dietary differences, there may be inter-indivi-
dual differences in absorption, utilization, storage and
excretion depending on host f a c t o r sa sw e l la se n v i r o n -
mental factors (e.g., oxidative stress) [6]. Yet, these bio-
markers are useful as an integrated measure of
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of these biomarkers for validating self-report instru-
ments has been pervasive [7] but somewhat problematic
since the biomarkers themselves do not represent a
direct measure of intake. The most that can be gathered
from such studies is the level of correlation between the
self-report and the biomarker, but it is unclear how to
use that correlation further.
Efforts to combine a “reference” self-report instrument
with one or more concentration biomarkers to validate
another self-report instrument [8-10] have relied on
assumptions regarding the correlations between errors.
See Rosner et al [11] for a recent review.
A second use of dietary biomarkers has been as stand-
alone risk factors for disease, for example serum choles-
terol for heart disease [12]. In this case, the finding of a
strong relationship to disease led to efforts to modify
the biomarker and thereby prevent the disease, either by
dietary means [13] or by medication [14].
I nt h i sp a p e rw ee x a m i n ead i f f e r e n tu s eo fd i e t a r y
biomarkers, especially concentration biomarkers,
namely, to strengthen tests of hypotheses regarding rela-
tionships between dietary intake and disease. The main
setting for application is in prospective cohort studies,
since biological samples can be taken before develop-
ment of disease, minimizing the risks of reverse causa-
tion. In fact, in many nutritional epidemiology studies
currently conducted, biological specimens, such as blood
samples, are collected from the participants, often in the
hope that they can be used to test as yet unidentified
hypotheses.
We describe methods that can be used for combining
self-reported dietary intake with a biomarker measure-
ment, and use computer simulations with realistic
inputs to demonstrate the levels of gain in efficiency
that can be achieved from the combination. The simula-
tions are based on the hypothesized diet-disease rela-
tionships between lutein and macular degeneration. (A
second example, beta-cryptoxanthin and stomach can-
cer, is provided in Additional File 1: Appendix, Part B.)
Our main aims are to bring this analytic strategy to the
attention of epidemiologists, to quantify the gains in sta-
tistical power to detect the diet-disease relationship that
could accrue from its use, and to discuss its limitations.
Analysis
The model
To elucidate some basic concepts involved in combining
dietary reports and biomarkers, we propose a simple
model in the form of a causal pathway diagram (Figure
1 c ) .I nt h ef i g u r e ,t h ea r r o wf r o md i e t a r yi n t a k et ob i o -
marker represents our assumption that true dietary
intake causally affects the true biomarker level. Conse-
quently, the two are correlated. Inasmuch as the
reported intake and the measured biomarker level are
correlated with their true values, they will also be corre-
lated with each other.
The model represented by Figure 1c postulates that
dietary intake affects disease through the biomarker and
also through other pathways. This is the most general
form of our model. For example, consider the potential
effect of N-nitroso compounds (NOC) from red meat
on colon cancer, with NOC-specific DNA adducts in
exfoliated colonocytes as biomarkers of NOC exposure
[ 1 5 , 1 6 ] .N O C st h a tr e a c ht h el a r g ei n t e s t i n eh a v ea
direct mutagenic effect on the colonic mucosa, resulting
in formation of NOC-specific DNA adducts in the colo-
nocytes, whereas absorbed NOCs can have a systematic
effect on colonic tissue, acting as tissue specific carcino-
gens, directly or after metabolic activation [16].
We also consider two sub-models. In the first submo-
del, the biomarker of intake is not a determinant of dis-
ease; thus, in Figure 1a the arrow between the marker
and disease is absent. For example, levels of urinary 3-
methyl-histidine, a marker for red meat intake [17] are
not thought to affect the risk of colon cancer, and
would add nothing to the risk model if the true dietary
intake were known. In the second submodel, dietary
intake does not affect risk except through the biomarker
(Figure 1b), and would add nothing to the risk model if
the true biomarker level were known. An example is the
dietary carotenoid intake, which is thought to affect skin
melanoma entirely through the level of carotenoid in
skin tissue [18].
When combining dietary reports with biomarkers in
searching for nutrition-disease relationships we are
using the biomarker in two different ways. Firstly, with
regard to the diet-disease pathway not mediated through
the biomarker, the biomarker acts as a correlate of diet-
ary intake and helps to improve precision of our mea-
sure of dietary intake. Secondly, with regard to the diet-
disease pathway through the biomarker, introduction of
the biomarker naturally strengthens our ability to detect
dietary effects through this pathway.
Finally, we note that Figure 1 does not include the
possibility of confounding variables that causally affect
the true biomarker level and independently the disease.
As noted earlier, individual differences in metabolism
and external factors can influence biomarker levels, so
t h ep r e s e n c eo fs u c hc o n f o u n d e r si sar e a lp o s s i b i l i t y .
We will proceed assuming that such confounding can
be controlled for in the analysis, and elaborate on this
important problem in the Discussion.
The statistical model
Parallel to the model depicted in Figure 1, we define a
statistical model. This will clarify the assumptions that
are being made, and will also form the basis for
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gains that can accrue from the combination methods
that we will describe.
The model, depicted in Figure 1, can be represented
mathematically by four inter-related statistical regression
models:
(i) Biomarker-Diet: relating true biomarker level (TBL)
to true dietary intake (TDI);
TBL TDI BL     01 ,
where the last term is distributed normally with mean
zero and constant variance, independently of dietary
intake. This part of the model describes the arrow from
true dietary intake to true biomarker level in Figures 1a-c.
(ii) Biomarker Measurement: relating measured bio-
marker level (MBL) to true biomarker level;
MBL TBL MBL   ,
where the last term is distributed normally with mean
zero and constant variance, independently of true
True 
biomarker 
level: TBL 
Reported 
dietary 
intake: RDI 
Measured 
biomarker 
level: MBL
Disease: D 
True 
dietary 
intake: TDI 
True 
biomarker 
level: TBL 
Reported 
dietary 
intake: RDI 
Measured 
biomarker 
level: MBL
Disease: D 
True 
dietary 
intake: TDI 
a
True 
biomarker 
level: TBL 
Reported 
dietary 
intake: RDI 
Measured 
biomarker 
level: MBL
Disease: D 
True 
dietary 
intake: TDI 
b
c
Figure 1 A-C: Pathway diagrams for three versions of the model. The variables typed in bold font are the observed variables; those in italic
font are unobserved. Figure 1a represents the model where the diet effect on disease is not mediated by the biomarker (no mediation). Figure
1b represents the model where the diet effect is entirely mediated by the biomarker (full mediation). Figure 1c represents the general form of
the model in which diet affects disease both through a pathway mediated by the biomarker and another pathway not mediated by the
biomarker (partial mediation).
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error model [19], and implies that the measured level is
an unbiased measure of the true level. This part of the
model describes the arrow from true biomarker level to
measured biomarker level in Figures 1a-c.
(iii) Dietary Intake Measurement: relating reported
dietary intake (RDI) to true intake;
RDI TDI RDI     01 ,
where the last term is distributed normally with mean
zero and constant variance, independently of true intake.
This part of the model describes the arrow from true
dietary intake to reported dietary intake in Figures 1a-c.
(iv) Disease-Diet: relating disease (D) to true dietary
intake and true biomarker level.
logit(Pr( )) . DT D I T B L   1 01 2  
In this model, the coefficient a2 represents the effect of
the biomarker level on disease, and describes the arrow
from true biomarker level to disease in Figure 1c; the
coefficient a1 represents the effect of diet on disease
through pathways independent of the biomarker and
describes the arrow from dietary intake to disease in Fig-
ure 1c. Assuming dietary intake causally affects biomar-
ker level, the total effect of diet is the sum of a1 plus a
multiple of a2. Setting a2 equal to zero is equivalent to
deleting the arrow from biomarker to disease, as in Fig-
ure 1a. Setting a1 equal to zero is equivalent to deleting
the arrow from dietary intake to disease, as in Figure 1b.
The main statistical assumptions underlying this four-
part model and implied by Figure 1c are as follows.
1. Measurement errors in dietary intake are indepen-
dent of disease, that is, non-differential.
2. Measurement errors in biomarker level are non-
differential.
3. Measurement errors in dietary intake and in bio-
marker level are independent of each other. This seems
reasonable since reporting errors are mostly cognitive
whereas biomarker errors are mostly related to physiol-
ogy or to laboratory conditions.
4. Any confounders of the biomarker-disease relation-
ship and of the dietary intake-disease relationship have
been controlled for (and are thus omitted from Figure
1). This is the strongest assumption, and we elaborate
on it in the Discussion.
The assumptions regarding linearity of the regression
models are not central to the main argument in this
paper. If any of the regressions is non-linear then the
dietary intake or biomarker level may be replaced by an
appropriately transformed variable that will conform
more closely to a linear relationship. Such transforma-
tion would not substantially change the results regarding
statistical efficiency reported here.
Statistical Methods of Relating Self-reported Intake and
Biomarker Level to Disease
We assumed that: each cohort participant provides a
self-reported dietary intake, a related biomarker mea-
surement, and a binary disease outcome; self-report and
biomarker values are transformed, if necessary, so their
distributions are approximately normal; and relation-
ships between dietary intake and disease are to be inves-
tigated using logistic regression. We considered 5
analytic approaches; the last three represent different
ways of combining self-report and biomarker.
1. Univariate analysis (i.e. logistic regression with one
explanatory variable) of self-reported intake;
2. Univariate analysis of biomarker level;
3. Bivariate analysis (i.e. logistic regression with two
explanatory variables) of self-reported intake and bio-
marker level, testing the joint null hypothesis that the
coefficients for self-reported intake and biomarker level
a r es i m u l t a n e o u s l yz e r o .T h i sjoint hypothesis uniquely
represents no association between diet and disease,
assuming that dietary intake and biomarker do not
affect disease in opposing directions.
4. Howe’s method [20]. The two variables are grouped
into k quantile groups, and the score j1 + j2 is calcu-
lated, where j1 is a participant’sq u a n t i l ef o rs e l f -
reported intake and j2 the quantile for biomarker level.
The score is then used as the explanatory variable in the
logistic regression. For k = 5, the range of possible
scores is from 2 to 10. We studied the versions of the
method with k = 3, 4, 5 and n (the sample size). With
the last version, the score is the sum of the ranks of the
two variables. We present results for this last version, as
it was consistently the most efficient in our simulations.
5. Univariate analysis of the first principal components
score. Principal components analysis [21] is performed
on self-reported diet and biomarker level, the first prin-
cipal component is formed and the scores of the first
component are computed for each participant. Logistic
regression is then conducted with the score as the
explanatory variable. Principal components analysis is
conducted on the correlation matrix, and the first prin-
cipal component is the sum of the reported dietary
intake and biomarker level weighted by the inverse of
their respective standard deviations.
Computer simulations
For simulating data, values of the coefficients in each of
the four models described above must be specified, as
well as the means and variances of the variables. Our
aim was to quantify the potential gains in statistical
power from using combined diet-biomarker analyses in
realistic situations. We therefore chose two diet-disease
hypotheses (to be described), and used results from the
literature to determine the parameters for the
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and age-related macular degeneration (ARMD).
There is now considerable evidence that dietary lutein
intake could reduce the incidence of ARMD [22].
Lutein, found in dark green, leafy vegetables is found in
the macula and is thought to be protective though its
antioxidant functions and as a blue light filter that pro-
tects underlying tissue from light damage [22,23]. Macu-
lar degeneration is an irreversible process that is a major
cause of blindness in the elderly, and may be preventa-
ble through increased intake of lutein as well as zeax-
anthin, by increasing the macular pigment [22].
The biomarker that we considered for dietary lutein
intake was serum lutein. We considered two possible
methods for self-report of lutein intake: a food fre-
quency questionnaire (FFQ) or 6 repeated 24 hour
recalls (24 HR). The FFQ is the instrument most com-
monly used to assess dietary intake in large prospective
studies. Multiple 24 HR’s are hypothesized to be more
accurate than a FFQ [24] and are becoming more feasi-
ble to apply in large studies with the development of
computerized versions [25].
To choose the parameters for the simulations, we
scanned the literature for carotenoid feeding studies
[26-29], cross-sectional studies of self-reported carote-
noid intake and serum carotenoid levels [30-32], and
epidemiologic studies relating carotenoid intake or
serum levels to ARMD [33]. We also used unpublished
data from the OPEN study [34]. The values of the para-
meters are shown in Table 1 and their determination is
described in Additional File 1: Appendix, Part A.
The second example, beta-cryptoxanthin and stomach
cancer, is fully described in Additional File 1: Appendix,
Part B.
We simulated cohort studies with 400 individuals,
approximately half developing the disease, the other half
remaining disease-free. One may regard these as repre-
senting nested case-control studies arising from cohort
studies with a low incidence rate. To the data from each
study, we applied the five statistical analyses listed
previously.
After applying each analysis, we examined (a) whether
a statistically significant relationship between disease
and exposure was found at the 5% level on a two-sided
test, and (b) the estimated RR between the 90
th and 10
th
percentiles of the exposure variable distribution. For RR,
Howe’sm e t h o dc o u l dn o tb ec o m p a r e dw i t ht h eo t h e r
methods.
We examined 6 scenarios, three where the dietary
report instrument was a FFQ and three where it was 6
repeats of a 24 HR. Each set of three scenarios comprised
a disease risk model where the dietary effect on disease
was not mediated through the biomarker (no mediation,
as in Figure 1a), a model of full mediation (as in Figure
1b), and a model of partial mediation (as in Figure 1c).
For each scenario we simulated 1000 cohort studies.
From the results on each scenario, we estimated statis-
tical power as the proportion of statistically significant
results, and the geometric mean of the RRs. We con-
verted differences in statistical power to the ratio of
sample size required to that required if a univariate ana-
lysis of reported dietary intake were used. This conver-
sion was based on assuming that the test statistics were
normally distributed.
Results: Correlations between the exposure variables
T h ec h o s e nm o d e lp a r a m e t e r ss h o w ni nT a b l e1g a v e
rise to correlations between the exposure variables
(Table 2). True dietary intake (TDI) was most strongly
correlated with 6 × 24 HR reported intake (0.68), some-
what less strongly correlated (0.61) with observed serum
lutein level (MBL), and least strongly correlated with
FFQ reported dietary intake (0.51). True serum lutein
Table 1 Parameters for the Lutein - Age Related Macular
Degeneration Model
Model Parameter Value*
Biomarker-Diet
a Intercept b0 5.29
Slope b1 0.60
Residual
variance(εBL)
0.10
Biomarker
Measurement
b
Mean(TBL) 5.60
Variance(TBL) 0.19
Residual
variance
(εMBL)
0.05
FFQ 6 ×
24 HR
Intercept g0 0.35 0.08
Slope g1 0.71 0.84
Dietary Intake
Measurement
c
Mean(TDI) 0.51
Variance(TDI) 0.25
Residual
variance(εRDI)
0.36 0.20
Disease-Diet
d Model
a
Model
b
Model
c
Intercept a0 0.51 6.72 3.77
Coefficient
a1
-1.00 0.00 -0.48
Coefficient
a2
0.00 -1.20 -0.63
* Biomarker level is log transformed nmol/L; Dietary intake is log transformed
mg/d. Parameter values are derived from data in references: Van het Hoff et
al[26], Brevik et al[28], Delcourt et al[33], Dixon et al[30], Mares et al[31] and
on unpublished data from the OPEN study[34], as described in Additional File
1: Appendix, Part A.
a Parameters for regression of TBL on TDI
b Parameters for regression of MBL on TBL
c Parameters for regression of RDI on TDI
d Parameters for regression of disease D on TBL and TDI
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serum lutein level (0.89), and not very highly correlated
with reported dietary intake (0.47 for 6 × 24 HR and
0.35 for FFQ).
Simulation results
Results for scenarios where a FFQ was the dietary instru-
ment are shown in Table 3. Estimated RRs (between the
90
th and 10
th percentiles of the measured exposure) were
less than one, indicating the protective effect of lutein.
For univariate analyses they varied between 0.32 and 0.64
according to the disease risk model and method of analy-
sis. In most cases, the lower the RR in univariate analyses,
the higher was the statistical power.
The univariate analysis of FFQ reported intake was
less powerful than that of serum level. This was due to
FFQ reported intake having a lower correlation with
true dietary intake (r = 0.51) and with true serum level
(0.35) than did measured serum level (0.61 and 0.89
respectively) (Table 2).
The combination methods generally performed much
better than the univariate analysis of FFQ. Whether or
not they improved on the univariate analysis of serum
level depended on the disease risk model. When there
was no mediation through the serum level, combination
methods, especially principal components, produced
moderate gains over the analysis of serum level alone.
When there was partial mediation, principal compo-
nents was only slightly more efficient than using serum
level alone. When there was full mediation, then the
univariate serum level analysis was optimal, although
the principal components method was not much
inferior.
Among the combination methods, principal compo-
nents and Howe’s method performed equally well.
Bivariate analysis was less powerful than univariate ana-
lysis of serum level in the models with full and partial
mediation, and less powerful than principal components
and Howe’s method in the models with no or partial
mediation through the biomarker.
Projected sample size savings compared to univariate
analysis of FFQ were substantial. Under full mediation
the univariate serum analysis would require only 16% of
the sample size needed for a dietary intake analysis, and
under partial mediation 32%. Combination methods also
gave substantial sample size savings, with the principal
components yielding sample sizes between 21% (full
mediation) and 52% (no mediation) of that required for
univariate analysis of FFQ. In parallel with these sample
size savings, observed RRs between the 10
th and 90
th
percentiles were well below 0.5 using univariate serum
Table 2 Lutein: Correlations Between Measurements Derived From the Chosen Model
True diet lutein
(TDI)
Reported diet lutein (RDI) True serum lutein
(TBL)
Measured serum lutein (MBL)
FFQ 6 × 24 HR
TDI 1.00
RDI FFQ 0.51 1.00
6 × 24 HR 0.68
TBL 0.69 0.35 0.47 1.00
MBL 0.61 0.31 0.42 0.89 1.00
Table 3 Lutein and Age Related Macular Degeneration
(ARMD), With Dietary Intake Assessed by FFQ:
Standardized Relative Risks (RR*), Statistical Power and
Relative Sample Size** (rss) Required for Various Analysis
Strategies Under Different Disease Risk Models
Analysis
Strategy
Disease Risk Model
(a)
Not
mediated
through
marker
(b)
Mediated
entirely
through
marker
(c)
Partially
mediated
through
marker
RDI
a
(univariate)
RR
Power
(rss)
0.54
0.655 (1.00)
0.64
0.413 (1.00)
0.58
0.533 (1.00)
MBL
b
(univariate)
RR
Power
(rss)
0.47
0.814 (0.68)
0.32
0.993 (0.16)
0.38
0.952 (0.32)
Bivariate
c RR RDI
RR
MBL
Power
(rss)
0.65
0.54
0.839 (0.64)
0.90
0.33
0.986 (0.18)
0.76
0.41
0.941 (0.34)
Howe
d
(ranks)
RR
Power
(rss)
0.42
0.891 (0.55)
0.36
0.958 (0.22)
0.38
0.948 (0.32)
Principal
Components
e
RR
Power
(rss)
0.43
0.904 (0.52)
0.37
0.966 (0.21)
0.39
0.956 (0.31)
* Standardized relative risk is defined as the RR between the 90
th and 10
th
percentiles of the distribution.
Bold type indicates the most powerful method among the available choices
investigated.
** Sample size requirement relative to the univariate RDI analysis.
a Regression of ARMD on RDI
b Regression of ARMD on MBL
c Regression of ARMD on RDI and MBL
d Regression of ARMD on combination of RDI and MBL using Howe’s method
e Regression of ARMD on combination of RDI and MBL using Principal
Components
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univariate analysis of FFQ.
Results where 6 24 HR’s were the dietary instrument are
shown in Table 4. These results show that when the diet-
ary instrument was improved (correlation with true intake
= 0.68), the gains from including the serum biomarker
were less dramatic but still potentially useful. In the no
mediation model, univariate analysis of 24 HR’sg a v em o r e
statistical power than univariate analysis of serum level,
but was less powerful than the principal components
method. The latter yielded a sample size requirement 77%
that of the univariate analysis of 24 HR’s.
When there was partial or full mediation through the
serum level, then the power gains from univariate analy-
sis of serum level and from the combination methods
were substantial, with reduction of sample size to 30%-
50%, relative to analysis of 24 HR’s. However, in these
models the combination methods did not perform better
than the univariate serum level analysis.
The results for b-cryptoxanthin and stomach cancer
were quite similar to those shown in Tables 3 and 4,
and are described in Additional File 1: Appendix, Part B.
Comments on the application of the method
The principal component or Howe’s score has no recog-
nized units, the first being a sum of two standardized
scores, the second a sum of two rank scores. Other
nutritional measures, such as “prudent diet” scores or
the Healthy Eating Index, share this property. We pro-
pose that the principal components score be used as a
more efficient first means of establishing the existence
of a nutrition-disease relationship. Analyses that explore
in more depth the relationships between dietary intake,
biomarker level and disease risk will be motivated by
such a positive result.
Markers that will be potentially useful in combination
with dietary reports are those demonstrated in controlled
feeding studies to be quantifiably modified by changes in
diet. A causal relationship between marker and disease
then implies that dietary intake will also affect disease,
making it acceptable to combine the two measures. The
level of the correlation between biomarker and reported
dietary intake need not be high. In fact, from simulations
not reported here, it appears that biomarkers are likely to
be most helpful when reported intake is a poor measure
of true intake, and in this situation the reported intake
will also have low correlation with the biomarker. What
is important is that the biomarker has a correlation with
true intake that is similar, or preferably higher, than the
correlation between reported intake and true intake.
Some notion of whether this is so may be available from
controlled feeding studies.
Another helpful characteristic is that the biomarker is
not known to be affected by risk factors for the disease.
This is related to the assumptions implicit in Figure 1. If
there were risk factors that affected the biomarker, then
the biomarker-disease association would be at least
partly indirect. Factors that affect the metabolism of the
dietary constituent or interact to change the biomarker
levels, such as hypo-absorption or oxidative stress, may
also have independent effects on the disease, and could
thereby confound the diet-biomarker-disease relation-
ship. In the worst case, modifying the biomarker level
through diet change would not affect disease. The pro-
blem here is the familiar one of confounding that has
been a consideration in previous studies of biomarkers
and disease. In the event that a strong risk factor for the
disease is known to affect the marker, that risk factor
should at least be included in the disease risk model so
as to avoid ascribing its effect as nutritional. For exam-
ple, there is now some evidence that beta-cryptoxanthin
is negatively associated with smoking [35], and smoking
is a known risk factor for stomach cancer [36]. Thus,
Table 4 Lutein and Age Related Macular Degeneration
(ARMD), With Dietary Intake Assessed by 6 24 HR’s:
Standardized Relative Risks (RR*), Statistical Power and
Relative Sample Size** (rss) Required for Various Analysis
Strategies Under Different Disease Risk Models
Analysis
Strategy
Disease Risk Model
(a)
Not
mediated
through
marker
(b)
Mediated
entirely
through
marker
(c)
Partially
mediated
through
marker
RDI
a
(univariate)
RR
Power
(rss)
0.43
0.890 (1.00)
0.55
0.629 (1.00)
0.49
0.810 (1.00)
MBL
b
(univariate)
RR
Power
(rss)
0.47
0.829 (1.20)
0.32
0.995 (0.25)
0.38
0.972 (0.54)
Bivariate
c RR RDI
RR
MBL
Power
(rss)
0.53
0.61
0.904 (0.95)
0.87
0.33
0.986 (0.30)
0.67
0.44
0.968 (0.55)
Howe
d
(ranks)
RR
Power
(rss)
0.38
0.959 (0.74)
0.34
0.985 (0.31)
0.35
0.974 (0.53)
Principal
Components
e
RR
Power
(rss)
0.39
0.952 (0.77)
0.35
0.984 (0.31)
0.37
0.977 (0.51)
* Standardized relative risk is defined as the RR between the 90
th and 10
th
percentiles of the distribution.
Bold type indicates the most powerful method among the available choices
investigated.
** Sample size requirement relative to the univariate RDI analysis.
a Regression of ARMD on RDI
b Regression of ARMD on MBL
c Regression of ARMD on RDI and MBL
d Regression of ARMD on combination of RDI and MBL using Howe’s method
e Regression of ARMD on combination of RDI and MBL using Principal
Components
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to a combined measure of dietary intake/serum level of
beta-cryptoxanthin. Thus, a price to pay for using a
combined dietary intake-biomarker measure is the extra
care needed in considering confounding factors since
these could enter both through confounding with self-
reported intake or through confounding with the bio-
marker level, and the uncertainty over whether introdu-
cing the biomarker has actually introduced an
unwelcome confounder alongside the extra information
on dietary intake. Here again, the higher is the correla-
tion between the biomarker level and true intake, the
more likely is the success of our proposed analytic strat-
egy. For example, our analysis of the literature indicates
an encouragingly high correlation of 0.69 between
serum lutein and true dietary lutein intake (Table 2).
The practicality of including biomarker measurements
in all participants in a large cohort study needs consid-
ering. As mentioned in the introduction, collecting bio-
l o g i c a ls a m p l e sf r o mp a r t i c i p a n t si sn ol o n g e r
uncommon and their uses are manifold. Thus, while
sample collection can be extremely expensive, the pro-
posed approach may be feasible for studies with an
already established “biobank”. Furthermore, the sample
size savings shown in Tables 3-4 indicate that adding a
biomarker could lead to a two- to five-fold decrease in
required sample size, which may partly offset the extra
cost of collecting the specimens. Note that the analytic
cost of the bioassays need not be prohibitive if analyses
are based on a nested case-control design.
Conclusion
We have demonstrated through computer simulation
that including biomarkers in nutrition-disease analyses
of prospective studies can substantially increase the sta-
tistical power for detecting a relationship and thereby
reduce sample size requirements. The simulation model
is relatively simple, but contains the statistical essentials
necessary to analyze the problem and provide insight.
An advantage of the simulations performed is that the
input parameters are based on data from the literature.
Comparison of the results in Table 3 (FFQ) with those
in Table 4 (6 × 24 HR’s) show that the biomarker con-
tributes incrementally less when the dietary report is
more accurate, but the results under full and partial
mediation models in Table 4 show that there remains
room for further substantial increases in power from
including biomarker data.
We will often be ignorant of the extent to which diet-
ary intake effects are mediated by the biomarker. There-
fore we need methods that perform well under different
disease risk models. In our limited simulations, the prin-
cipal components method and Howe’sm e t h o db o t h
seemed to do this. They were superior to univariate
biomarker analysis under the no mediation model and
were not substantially inferior to that analysis under full
mediation. Thus when we are ignorant of the extent to
which the biomarker mediates the dietary effect, a com-
bination approach using either of these methods would
appear to be a good strategy. Howe’s method has in fact
been used, with apparently useful results, in two reports
exploring carotenoid intake and prostate cancer [37,38].
In circumstances where we know that full mediation
through the biomarker occurs, we should use the uni-
variate analysis of the biomarker level rather than a
combination method, as long as the biomarker measure-
ment has relatively little measurement error.
In summary, the added information and statistical
power demonstrated in our simulations suggest that
including biomarker data in addition to the usual dietary
data in a cohort could greatly strengthen the investiga-
tion of diet-disease relation s h i p s ,a n dt h a t ,w h e nt h e
extent of mediation through the biomarker is unknown,
use of a combination method such as principal compo-
nents or Howe’s method appears a good strategy.
Additional file 1: Detailed calculations of the parameters for the
simulations and further results. Contains (a) data from the papers in
the literature on lutein intake, serum lutein and macular degeneration
and how they are used to calculate the parameters in the proposed
statistical model; (b) data from the papers in the literature on beta-
cryptoxantin intake, serum beta-cryptoxanthin and stomach cancer and
how they are used to calculate the parameters in the proposed statistical
model; and (c) tables presenting results of simulation of the model for
beta-cryptoxanthin and stomach cancer.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-5573-7-2-
S1.DOC]
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